A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea

PHASE3CompletedINTERVENTIONAL
Enrollment

377

Participants

Timeline

Start Date

October 7, 2024

Primary Completion Date

February 3, 2025

Study Completion Date

February 3, 2025

Conditions
Respiratory Syncytial Virus
Interventions
BIOLOGICAL

RSVpreF Vaccine

RSV Vaccine 120 mcg

OTHER

Placebo

Placebo

Trial Locations (16)

14584

Soon Chun Hyang University Bucheon Hospital, Bucheon-si

15355

Korea University Ansan Hospital, Ansan-si

16247

The Catholic University Of Korea St. Vincent's Hospital, Suwon

16499

Ajou University Hospital, Suwon

22332

Inha University Hospital, Incheon

41944

Kyungpook National University Hospital, Daegu

49201

Dong-A University Hospital, Busan

54907

Jeonbuk National University Hospital, Jeonju

61469

Chonnam National University Hospital, Gwangju

03722

Severance Hospital, Yonsei University Health System, Seoul

05355

Hallym University Kangdong Sacred Heart Hospital, Seoul

06351

Samsung Medical Center, Seoul

06591

The Catholic Univ. of Korea Seoul St. Mary's Hospital, Seoul

07441

Hallym University Kangnam Sacred Heart Hospital, Seoul

07985

Ewha Womans University Mokdong Hospital, Seoul

08308

Korea University Guro Hospital, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06593587 - A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea | Biotech Hunter | Biotech Hunter